drupalma

SUPIRA MEDICAL, INC., A SHIFAMED PORTFOLIO COMPANY, RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION AS THE COMPANY CLOSED $40M IN SERIES D FINANCING

by ·

SUPIRA MEDICAL, INC., A SHIFAMED PORTFOLIO COMPANY, RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION AS THE COMPANY CLOSED $40M IN SERIES D FINANCING
LOS GATOS, Calif., Nov. 21, 2023 /PRNewswire/ — Supira Medical, Inc., a Shifamed portfolio firm, introduced in the present day that it has acquired U.S. Meals and Drug Administration (FDA) breakthrough gadget designation for its Supira System, a next-generation percutaneous ventricular help gadget (pVAD). This approval comes as the corporate closed $40M in Collection D financing and prepares to provoke its U.S. scientific program. The financing was led by Cormorant Asset Administration and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC fund, Unorthodox Ventures and Shifamed angel traders. Funds will probably be used to develop Supira’s presently enrolling OUS research, plan for its U.S. research, and put together for U.S. pivotal examine submission.

“We’re thrilled to have acquired breakthrough gadget designation and happy to have the robust, continued assist from our traders, each important milestones for the corporate,” commented Dr. Nitin SalunkePresident and CEO of Supira Medical. “Early scientific expertise with the Supira System has demonstrated that physicians see super scientific worth in Supira’s low profile, excessive steady circulation design, together with the system’s sensors meant to gather real-time aortic and ventricular pressures. I congratulate the workforce for engineering this differentiated answer that goals to offer a significant benefit for sufferers requiring hemodynamic assist.”

“Though non permanent mechanical circulatory assist is widespread within the therapy of high-risk sufferers, challenges stay that restrict doctor adoption and affected person entry,” acknowledged Bihua Chen, Founder and Managing Member of Cormorant Asset Administration. “We’re happy to steer this spherical and consider that Supira’s expertise has the potential to disrupt the usual of look after the big and rising HRPCI phase of the interventional cardiology market.”

In regards to the Supira System
With a novel low profile, excessive steady circulation design, the Supira System goals to offer full hemodynamic assist initially for high-risk percutaneous coronary interventions (HRPCI) and subsequently for cardiogenic shock (CS) sufferers with a single gadget platform. The Supira System incorporates a 10F profile, designed to reduce vascular issues, and a number of sensors to offer real-time stress measurements.

The Supira System is for Investigational Use Solely and isn’t on the market within the U.S. or outdoors the U.S.

About Supira Medical, Inc.
Supira Medical is a privately held portfolio firm of Shifamed, LLC., a extremely specialised medical innovation hub based by serial entrepreneur, Amr Salahieh. The corporate is concentrated on creating the following technology percutaneous ventricular help gadget to be used in high-risk sufferers present process interventional procedures. For extra info, go to www.supiramedical.com.

MEDIA CONTACT:
Charlene Herndon
SPRIG Consulting LLC
(e-mail protected)

SOURCE Supira Medical, Inc.

Tags:

You may also like...

Leave a Reply